SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. She will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations.
The appointment comes as SS Innovations seeks to make robotic surgery more affordable and accessible worldwide. The company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For more details, the full press release is available at https://ibn.fm/pAqlP.
About SS Innovations: SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population.
Forward-Looking Statements: Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
